IOVANCE BIOTHERAPEUTICS, INC. Financials Iovance Biotherapeutics, Inc.
Equities
IOVA
US4622601007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.64 USD | +0.87% |
|
+2.92% | +43.17% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,493 | 6,806 | 2,995 | 1,009 | 2,081 | 3,251 | - | - |
| Enterprise Value (EV) 1 | 3,181 | 6,177 | 2,492 | 531.3 | 1,735 | 3,118 | 3,001 | 2,747 |
| P/E ratio | -17.4 x | -24.7 x | -8.56 x | -2.57 x | -4.3 x | -8.97 x | -16.1 x | 154 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 1,750 x | 20.1 x | 7.87 x | 4.75 x |
| EV / Revenue | - | - | - | - | 1,459 x | 19.3 x | 7.27 x | 4.01 x |
| EV / EBITDA | - | -23.7 x | -7.34 x | -1.36 x | -3.86 x | -10.3 x | -19 x | -13.8 x |
| EV / FCF | -19.2 x | -24.5 x | -9.38 x | -1.7 x | -4.52 x | -11.7 x | -19.4 x | 27.1 x |
| FCF Yield | -5.21% | -4.08% | -10.7% | -58.9% | -22.1% | -8.56% | -5.14% | 3.69% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 126,195 | 146,687 | 156,899 | 157,841 | 255,918 | 279,307 | - | - |
| Reference price 2 | 27.68 | 46.40 | 19.09 | 6.390 | 8.130 | 11.64 | 11.64 | 11.64 |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 1.189 | 161.4 | 413 | 685 |
| EBITDA 1 | - | -260.8 | -339.6 | -389.6 | -449 | -302.4 | -157.6 | -199.4 |
| EBIT 1 | -206.9 | -261.9 | -342.7 | -398.9 | -460.6 | -358.6 | -221.2 | 5.762 |
| Operating Margin | - | - | - | - | -38,734.99% | -222.14% | -53.55% | 0.84% |
| Earnings before Tax (EBT) 1 | -197.6 | -259.6 | -342.3 | -395.9 | -447.5 | -352.5 | -233.3 | 25.08 |
| Net income 1 | -197.6 | -259.6 | -342.3 | -395.9 | -444 | -352.5 | -245 | 6.532 |
| Net margin | - | - | - | - | -37,345.42% | -218.32% | -59.32% | 0.95% |
| EPS 2 | -1.590 | -1.880 | -2.230 | -2.490 | -1.890 | -1.298 | -0.7210 | 0.0757 |
| Free Cash Flow 1 | -165.8 | -251.9 | -265.5 | -313.2 | -384.1 | -267 | -154.3 | 101.2 |
| FCF margin | - | - | - | - | -32,305.3% | -165.38% | -37.37% | 14.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 1,550.09% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 0.238 | 0.469 | 0.482 | 2.088 | 30.47 | 60.58 | 77.33 | 119 |
| EBITDA 1 | - | -98.12 | -89.92 | -97.49 | -97.94 | -104.2 | -108.1 | -107.2 | - | - | -128 | -129.4 | -128.4 | -131.6 | - |
| EBIT 1 | -86.24 | -99.46 | -91.71 | -99.73 | -100.4 | -107 | -110.9 | -110.1 | -118.4 | -121.3 | -111.4 | -97.7 | -75.97 | -67.03 | -43.75 |
| Operating Margin | - | - | - | - | - | - | - | -46,254.62% | -25,236.89% | -25,156.85% | -5,332.48% | -320.67% | -125.41% | -86.68% | -36.76% |
| Earnings before Tax (EBT) 1 | -86.12 | -99.33 | -91.61 | -99.35 | -99.62 | -105.3 | -107.4 | -107 | -115 | -118.1 | -113 | -98.16 | -78.45 | -73.14 | -40.82 |
| Net income 1 | -86.12 | -99.33 | -91.61 | -99.35 | -99.62 | -105.3 | -107.4 | -106.5 | -113.8 | -116.4 | -113 | -98.17 | -78.48 | -73.1 | -40.82 |
| Net margin | - | - | - | - | - | - | - | -44,759.66% | -24,255.86% | -24,145.02% | -5,411.11% | -322.22% | -129.56% | -94.53% | -34.31% |
| EPS 2 | -0.5500 | -0.6300 | -0.5800 | -0.6300 | -0.6300 | -0.6400 | -0.5000 | -0.4700 | -0.4600 | -0.4500 | -0.4300 | -0.3610 | -0.2890 | -0.2650 | -0.0550 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 313 | 629 | 503 | 477 | 345 | 133 | 251 | 504 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -166 | -252 | -266 | -313 | -384 | -267 | -154 | 101 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 6.92 | 46.8 | 37.6 | 20.4 | 22.3 | 15.1 | 19.3 | 19.3 |
| Capex / Sales | - | - | - | - | 1,874.68% | 9.37% | 4.68% | 2.82% |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
11.64
USD
Average target price
26
USD
Spread / Average Target
+123.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.17% | 3.25B | |
| -20.45% | 10.82B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M | |
| +13.32% | 332M |
- Stock Market
- Equities
- IOVA Stock
- Financials Iovance Biotherapeutics, Inc.
